A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay disease progression in men with specific DNA repair gene mutations. In the ...
TUESDAY, Oct. 21, 2025 (HealthDay News) -- For patients with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) gene alterations, the addition of ...
The FDA approved updated labeling for Talzenna plus Xtandi for HRR gene-mutated metastatic castration-resistant prostate cancer, based on the TALAPRO-2 trial results. The TALAPRO-2 trial showed a ...
Adding the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib to abiraterone acetate plus prednisone delayed disease progression and postponed the onset of symptoms in patients with metastatic ...
Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study 1.5% (82/5,404) had HRR gene homozygous loss, ...
Identification of variants influences treatment decisions. Inhibitors of the poly-ADP-ribose polymerase (PARP) system, a pathway for repairing single-stranded DNA breaks, are recommended for tumors ...
Significant improvement in radiographic progression-free survival seen first in BRCA subgroup. HealthDay News — For patients with metastatic castration-sensitive prostate cancer (mCSPC) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results